Bleeding and Cardiogenic Shock: An “Unholy Alliance”?

Courtesy of Dr. Carlos Fava.

Mortality in acute myocardial infarction (MI) with cardiogenic shock (CS) has been reduced over the past two decades. This has been possible thanks to early angioplasty, greater operator (and overall medical team) experience, new antiplatelet therapies, and ventricular assist devices, which have also been somewhat relevant in this setting.

Sangrado y shock cardiogénico ¿Es una asociación “ilícita”?

However, in MI without CS, bleeding is a well-known significant mortality factor. In CS, its mortality risk is 20% or more, and the use of ventricular assist devices increase it between 40% and 70%.

Its real incidence, the factors that cause it, and the severity of its prognosis have not been entirely studied yet.

A subanalysis of the CULPRIT-SHOCK trial included 684 patients. Among them, 147 had bleeding events (21.5%).

There were no differences among groups: the mean age was 70 years old, there was a higher proportion of men, most patients had an ST-segment elevation MI, and over half of them received CPR.


Read also: ESC 2018 | CULPRIT-SHOCK: 1-Year Results Continue to Support Treatment of the Culprit Artery Only.


A high percentage of bleeding events occurred within the first two weeks (57%); a third of them were classified as BARC 3, and 5.4% were fatal.

Patients with bleeding events received mechanical ventilation and treatment with vasoactive substances over a longer period of time. There was a significant association with sepsis, peripheral ischemic complications, new atrial fibrillation, and ventricular fibrillation.

At 30 days, the presence of bleeding events was associated with higher mortality (hazard ratio [HR]: 2.11; 95% confidence interval [CI]: 1.63 to 2.75; p < 0.0001), especially in cases of bleeding higher than 3b.


Read also: The CULPRIT-SHOCK Study Is Finally Published in NEJM and It Is Bound to Change Guidelines.


Extracorporeal membrane oxygenation (ECMO) and Impella were the main risk factors for bleeding.

Conclusion

Risk of bleeding in acute MI with cardiogenic shock is associated with increased mortality.

Courtesy of Dr. Carlos Fava.

Original Title: Frequency and Impact of Bleeding on Outcome in Patients With Cardiogenic Shock.

Reference: Anne Freund, et al. J Am Coll Cardiol Intv 2020;13:1182–93.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

ACC 2026 | DKCRUSH VIII: IVUS or angiography to guide PCI in complex coronary bifurcations

Intracoronary imaging guidance has become an established recommended strategy in complex coronary lesions. In the specific setting of complex bifurcations, uncertainty remained regarding the...

ACC 2026 | OPTIMAL: IVUS Guidance in PCI of the Unprotected Left Main Coronary Artery

Percutaneous coronary intervention (PCI) is considered an equivalent alternative to coronary artery bypass surgery in patients with left main coronary artery (LMCA) stenosis and...

ACC 2026 | IVUS-CHIP Trial: Intravascular ultrasound–guided versus angiography-guided complex PCI

Optimization of percutaneous coronary intervention (PCI) in complex lesions remains a relevant clinical challenge. In this context, the IVUS-CHIP trial was designed to evaluate...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...